MedPath

Evaluation of Etomidate on Adrenal Function in Trauma Patients

Not Applicable
Completed
Conditions
Adrenal Insufficiency
Interventions
Drug: RSI sedation with etomidate/succinylcholine
Drug: RSI sedation with fentanyl/midazolam/succinylcholine
Registration Number
NCT00462644
Lead Sponsor
University of Tennessee
Brief Summary

Trauma patients are at increased risk for adrenal function insufficiency. A commonly used agent for rapid sequence intubation (RSI) is known to decrease adrenal function. We want to determine the incidence of adrenocortical insufficiency and its significance during the first 24 hours of resuscitation following RSI in trauma patients.

Detailed Description

The study will have two arms. Patients on one arm will be assigned to receive etomidate (0.3 mg/kg) and succinylcholine (1mg/kg) for RSI. Patients on the other arm will receive standard therapy at this institution which consists of Versed (generic name midazolam) (5 mg) plus fentanyl (100 mcgs) as well as succinylcholine for RSI. Both drug regimens have a rapid onset, short duration and short half-life.

Patients will be randomly assigned to one arm of the study. The trauma nurse emergency room responders, intensive care unit staff, or helicopter crew will pull a study envelope which will contain a randomization to either the etomidate arm or standard therapy arm. The numbers will correspond to a log, delineating which medication is given. The nurse will document the medication as RSI Study Drug - etomidate or RSI Study Drug - standard and the randomization packet number (ie, RSI Study Drug, etomidate, #1, RSI Study Drug, standard, #2, etc.) and will document the patient's name and medical record number on the study log in either the helicopter or the ER Resuscitation Bay.

Baseline cortisol level will be drawn prior to RSI. An additional cortisol level will be drawn 4-6 hours later. Following this level, a cortrosyn stimulation test will be performed by giving 0.25 mg cortrosyn IV and rechecking a cortisol level in 60 minutes. Adrenal insufficiency will be defined as a baseline cortisol level of \<15 or an increase in cortisol of \<9 after cortrosyn administration. Patients will be monitored for 24 hours for hemodynamics, IV fluid administration , and use of vasopressors. Patient will be resuscitated to adequate mean arterial blood pressure and urine output. Any patient found to be adrenal insufficient will be treated with hydrocortisone 50 mg IV every 6 hours.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Trauma mechanism of injury
  • Patient requires rapid sequence induction for ventilatory support
Exclusion Criteria
  • <18 years old
  • Prisoners
  • Pregnant women
  • Patients with a history of adrenal insufficiency
  • Patients with adrenal trauma documented by CT scan
  • Patients receiving corticosteroids in the previous year

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EtomidateRSI sedation with etomidate/succinylcholineEtomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
Fentanyl-MidazolamRSI sedation with fentanyl/midazolam/succinylcholineFentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
Primary Outcome Measures
NameTimeMethod
Change in Baseline Cortisol4-6hr after RSI

change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test)

Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)60 minutes after administration of cotrosyn
Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Testpre RSI, 4-6 hours post RSI, and again 60 mins later following ACTH stimulation test
Postintubation Cortisol (Baseline Cortisol Level)postintubation (baseline cortisol level)

cortisol level after randomization and rapid sequence induction

Secondary Outcome Measures
NameTimeMethod
Hospital Length of Staytime to hospital discharge in days

days from admission to hospital discharge

Intensive Care Unit (ICU) Length of Staytime from hospital admission to transfer out of ICU to floor bed

ICU length of stay in days

Ventilator Daystime from intubation to extubation
Number of Deathsdeath in hospital

deaths

Trial Locations

Locations (1)

Erlanger Medical Center

🇺🇸

Chattanooga, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath